Sai Ravi Pingali, MD

Associate Professor of Clinical Medicine, Academic Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Pingali is board certified by the American Board of Internal Medicine in medical oncology and hematology. His primary focus is on hematologic malignancies and stem cell transplantation. After completing his medical training in India, Dr. Pingali received training in various reputable programs in the United Kingdom as part of senior house officer training after which he moved to the United States. He completed his residency in internal medicine at Gundersen Lutheran Medical Center in Wisconsin. He then completed a fellowship in hematology and oncology at the Medical College of Wisconsin, and a fellowship in stem cell transplantation at the University of Texas MD Anderson Cancer Center.

Dr. Pingali is a member of the American Society of Clinical Oncology, American Society of Hematology and the American Society for Blood and Marrow Transplantation. He sees patients at Houston Methodist Hospital.

Publications

LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Mai, S, Hodges, A, Chen, HM, Zhang, J, Wang, YL, Liu, Y, Nakatsu, F, Wang, X, Fang, J, Xu, Y, Davidov, V, Kang, K, Pingali, SR, Ganguly, S, Suzuki, M, Konopleva, M, Prinzing, B, Zu, Y, Gottschalk, S, Lu, Y, Chen, SH & Pan, PY 2023, , Cancer research, vol. 83, no. 24, pp. 4047-4062. https://doi.org/10.1158/0008-5472.CAN-22-2483

Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry
Burns, EA, Sanchez, CG, Mathur, S, Guerrero, C, Muhsen, IN, Sarfraz, H, Hu, CCA, Tang, CHA, Shah, SS, Tremont, IW, Teh, B, Ganguly, S & Pingali, SRK 2023, , Annals of Hematology, vol. 102, no. 5, pp. 1111-1120. https://doi.org/10.1007/s00277-023-05140-6

Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry
Burns, EA, Wilson, JJ, Mathur, S, Kieser, R, Gong, Z, Hu, CCA, Tang, CHA, Petkova, J, Yuen, C, Mai, H, Shah, S, Rice, L, Ganguly, S & Pingali, SR 2023, , Annals of Hematology, vol. 102, no. 10, pp. 2753-2763. https://doi.org/10.1007/s00277-023-05328-w

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
Su, P, Xiao, L, Ye, L, Wang, Z, Xiong, W, Wang, Q, Ma, X, Xian, M, Yang, M, Zu, Y, Pingali, SR, Qian, J & Yi, Q 2022, , Journal of Hematology and Oncology, vol. 15, no. 1, 55, pp. 55. https://doi.org/10.1186/s13045-022-01269-5

RAR? activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Wang, Q, Lin, Z, Wang, Z, Ye, L, Xian, M, Xiao, L, Su, P, Bi, E, Huang, YH, Qian, J, Liu, L, Ma, X, Yang, M, Xiong, W, Zu, Y, Pingali, SR, Xu, B & Yi, Q 2022, , Blood, vol. 139, no. 1, pp. 59-72. https://doi.org/10.1182/blood.2020009856

Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma
Friend, BD, Muhsen, IN, Patel, S, Hill, LQC, Lulla, P, Ramos, CA, Pingali, SR, Kamble, RT, John, TD, Salem, B, Bhar, S, Doherty, EE, Craddock, J, Sasa, G, Wu, M, Wang, T, Martinez, C, Krance, RA, Heslop, HE & Carrum, G 2022, , Bone Marrow Transplantation, vol. 57, no. 4, pp. 579-585. https://doi.org/10.1038/s41409-022-01599-5

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma
Gentille, C, Sarfraz, H, Joshi, J, Randhawa, J, Shah, S & Pingali, SR 2022, , Cancer Reports, vol. 5, no. 7, e1581, pp. e1581. https://doi.org/10.1002/cnr2.1581

Loss of AID exacerbates the malignant progression of CLL
Lee, AC, Pingali, SR, Pinilla-Ibarz, JA, Atchison, ML, Koumenis, C, Argon, Y, Thomas-Tikhonenko, A, De Trez, C, Hu, CCA & Tang, CHA 2022, , Leukemia, vol. 36, no. 10, pp. 2430-2442. https://doi.org/10.1038/s41375-022-01663-5

Prognostic Effect of Systemic Therapy and Radiation Therapy in Stage I Nodal Marginal Zone Lymphoma
Chevli, N, Margolis, V, Haque, W, Pingali, SR, Butler, EB & Teh, BS 2023, , Practical Radiation Oncology, vol. 13, no. 1, pp. e80-e93. https://doi.org/10.1016/j.prro.2022.10.001

RAR? activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Wang, Q, Lin, Z, Wang, Z, Ye, L, Xian, M, Xiao, L, Su, P, Bi, E, Huang, YH, Qian, J, Liu, L, Ma, X, Yang, M, Xiong, W, Zu, Y, Pingali, SR, Xu, B & Yi, Q 2022, , Blood, vol. 139, no. 1, pp. 59-72. https://doi.org/10.1182/blood.2020009856, https://doi.org/10.1182/blood.2020009856

G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
Youssef, JG, Zahiruddin, F, Youssef, G, Padmanabhan, S, Ensor, J, Pingali, SR, Zu, Y, Sahay, S & Iyer, SP 2021, , Annals of Hematology, vol. 100, no. 3, pp. 667-673. https://doi.org/10.1007/s00277-021-04395-1

Yeni jenerasyon proteozom inhibitörleriyle olan çevresel nöropati yükünün fda yan etki raporlama sistemi kullanilarak pazarlama sonrasi analizi
Mina, SA, Muhsen, IN, Burns, EA, Sarfraz, H, Pingali, SR, Xu, J & Hashmi, SK 2021, , Turkish Journal of Hematology, vol. 38, no. 3, pp. 218-221. https://doi.org/10.4274/tjh.galenos.2021.2021.0052

Primary cutaneous anaplastic large-cell lymphoma: a review of the SEER database from 2005 to 2016
Sarfraz, H, Gentille, C, Ensor, J, Wang, L, Wong, S, Ketcham, MS, Joshi, J & Pingali, SRK 2021, , Clinical and Experimental Dermatology, vol. 46, no. 8, pp. 1420-1426. https://doi.org/10.1111/ced.14777

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
Sirimaturos, M, Gotur, DB, Patel, SJ, Dreucean, D, Jakowenko, N, Cooper, MH, Brahmbhatt, N, Graviss, EA, Nguyen, DT, Pingali, SR, Lin, J & Musick, WL 2020, , Critical care explorations, vol. 2, no. 10, pp. e0232. https://doi.org/10.1097/CCE.0000000000000232

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
Sirimaturos, M, Gotur, DB, Patel, SJ, Dreucean, D, Jakowenko, N, Cooper, MH, Brahmbhatt, N, Graviss, EA, Nguyen, DT, Pingali, SR, Lin, J & Musick, WL 2020, , Critical care explorations, vol. 2, no. 10, pp. E0232. https://doi.org/10.1097/CCE.0000000000000232

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
Anand, K, Sahu, G, Burns, E, Ensor, A, Ensor, J, Pingali, SR, Subbiah, V & Iyer, SP 2020, , ESMO Open, vol. 5, no. 4, e000866. https://doi.org/10.1136/esmoopen-2020-000866

Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: A case report and review of the literature
Kasparian, S, Burns, E, Shehabeldin, A, Awar, M & Pingali, SR 2020, , Journal of Medical Case Reports, vol. 14, no. 1, 127. https://doi.org/10.1186/s13256-020-02449-y

Radiation therapy in primary mediastinal large B-cell lymphoma treated with DA-R-EPOCH
Gentille, C, Anand, K, Dalwadi, S, Puri, A, Farach, A & Pingali, SR 2020, , Clinical Case Reports, vol. 8, no. 7, pp. 1153-1155. https://doi.org/10.1002/ccr3.2853

MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma
Wang, Q, Zhao, D, Xian, M, Wang, Z, Bi, E, Su, P, Qian, J, Ma, X, Yang, M, Liu, L, Zu, Y, Pingali, SR, Chen, K, Cai, Z & Yi, Q 2020, , Blood, vol. 136, no. 22, pp. 2557-2573. https://doi.org/10.1182/blood.2020005795

T-cell lymphoma secondary to checkpoint inhibitor therapy
Anand, K, Ensor, Jr. JE, Pingali, SR, Hwu, P, Duvic, M, Chiang, S, Miranda, R, Zu, Y & Iyer, S 2020, , Journal for immunotherapy of cancer, vol. 8, no. 1, e000104. https://doi.org/10.1136/jitc-2019-000104